TIANYU PHARM issued a profit forecast, expecting a net profit attributable to the parent company of 130 million to 180 million yuan in the first half of the year, a year-on-year increase of 144.29%-238.25%

TIANYU PHARM expects its net profit attributable to shareholders in the first half of 2025 to be between 130 million yuan and 180 million yuan, a year-on-year increase of 144.29%-238.25%. The net profit after deducting non-recurring gains and losses is expected to be between 121 million yuan and 171 million yuan, a year-on-year increase of 92.79%-172.45%. The company has improved the revenue scale and gross profit growth of its non-sartan active pharmaceutical ingredients and intermediates business, CDMO business, and formulation business through measures such as optimizing product structure, improving market layout, and strengthening cost control